Section Arrow
ASND.NASDAQ
- Ascendis Pharma A/S
Quotes are at least 15-min delayed:2024/05/16 06:09 EDT
Last
 124.04
-0.78 (-0.62%)
Day High 
128.25 
Prev. Close
124.82 
1-M High
150.19 
Volume 
998.21K 
Bid
49.62
Ask
197.22
Day Low
123.69 
Open
125.85 
1-M Low
116.625 
Market Cap 
7.07B 
Currency USD 
P/E -- 
%Yield
10-SMA 134.67 
20-SMA 137.57 
50-SMA 144.03 
52-W High 161 
52-W Low 83.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.87/-0.06
Enterprise Value
7.69B
Balance Sheet
Book Value Per Share
-4.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
266.72M
Operating Revenue Per Share
2.84
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 06:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.